A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.
dl-Methylphenidate (MPH) has been widely used to treat attention-deficit/hyperactivity disorder (ADHD) for the last half century. It had been exclusively available in the racemic form, i.e., a 50:50 mixture of d- and l-isomers. However, a single enantiomer formulation, d-MPH (dexmethylphenidate), became available for general clinical use in 2002. For this reason, the intrinsic pharmacological differences in the effects of d- and l-MPH have recently come under intense investigation. The primary therapeutic effects of MPH are generally recognized to reside in the d-isomer. The present investigation provides quantitative values for a broad range of receptor-level interactions of the individual MPH isomers to better characterize the distinction between dl-MPH versus d-MPH versus l-MPH as it relates to binding affinity at sites associated with relevant central nervous system (CNS) pharmacology, as well as peripheral physiology. Overall, there were few differences in binding affinities between d-MPH and the racemate whereas there were more apparent differences between d-MPH and l-MPH. d-MPH exhibited prominent affinity at the norepinephrine transporter (NET) site, even exceeding such affinity at the dopamine transporter (DAT). These results further demonstrate that affinity for catecholaminergic sites largely resides in the d-MPH isomer. Although binding affinity was not demonstrable at the serotonin (5-HT) transporter site (SERT), novel findings of the study included affinity for the 5-HT1A and 5-HT2B receptor sites for both d- and l-MPH, with d-MPH exerting by far the most predominant effects at these sites. Thus, the emerging data of favorable therapeutic effects of ADHD treatment with d-MPH (and dl-MPH) may be underpinned by affinity and potential pharmacologic effects at NET and DAT sites, as well as sites relevant to serotonergic neurotransmission that may modulate mood, cognition, and motor behavior. However, the present exploratory studies reflect receptor binding affinities only. The specific pharmacological activities (i.e., agonism vs. antagonism) of these compounds await further exploration.
Markowitz
John S
JS
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, USA. markowii@musc.edu
DeVane
C Lindsay
CL
Pestreich
Linda K
LK
Patrick
Kennerly S
KS
Muniz
Rafael
R
D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D002478:Cells, Cultured; D000697:Central Nervous System Stimulants / Q000737:chemistry* / Q000378:metabolism*; D064699:Dexmethylphenidate Hydrochloride; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D007536:Isomerism; D008774:Methylphenidate / Q000737:chemistry* / Q000378:metabolism*; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000378:metabolism; D011485:Protein Binding; D051381:Rats; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism; D044403:Receptor, Serotonin, 5-HT2B / Q000378:metabolism; D011955:Receptors, Drug / Q000737:chemistry / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000378:metabolism; D013237:Stereoisomerism
D002352:Carrier Proteins; D000697:Central Nervous System Stimulants; D050483:Dopamine Plasma Membrane Transport Proteins; D007473:Ion Channels; D050484:Norepinephrine Plasma Membrane Transport Proteins; D044403:Receptor, Serotonin, 5-HT2B; D011955:Receptors, Drug; D011976:Receptors, Muscarinic; D044282:Receptor, Serotonin, 5-HT1A; D064699:Dexmethylphenidate Hydrochloride; D008774:Methylphenidate